Hims & Hers’ big swing on growth — and a Super Bowl spotlight — has investors asking about profits
Hims & Hers built its brand by destigmatizing sensitive health issues and making treatment as simple as a few taps on a phone. That formula has delivered rapid revenue growth and a larger subscriber base, turning the company into a prominent direct-to-consumer telehealth platform. But its latest expansion push — coupled with the splashy decision to advertise during the Super Bowl, one of the priciest media buys in marketing — has renewed a familiar debate on Wall Street: how far and how fast can the company chase growth without denting profits?
What the company is trying to build
Hims & Hers has moved well beyond its early focus on men’s hair loss and erectile dysfunction. The company now sells a wide portfolio across men’s and women’s health, dermatology, mental health, and, increasingly, weight management. The strategy is straightforward: acquire customers with a targeted entry point, keep them with a smooth digital experience and ongoing clinician access, and grow lifetime value by cross-selling adjacent treatments and over-the-counter products.
Several expansion vectors are central to the next leg of growth:
– Weight management programs, including interest in GLP-1 medications, which could drive high average revenue per user but come with complex supply chains and hefty drug costs.
– Women’s health and dermatology, where brand trust and recurring needs create opportunities for long-duration subscriptions.
– Broader retail presence for over-the-counter products to bolster brand visibility and top-of-funnel awareness.
– More comprehensive care pathways, designed to deepen engagement and reduce churn through personalized plans and follow-ups.
Why the Super Bowl matters — and worries investors
Super Bowl advertising is marketing’s biggest stage and one of its most expensive line items; a 30-second national spot typically runs in the ballpark of $7 million before production and surrounding media. For Hims & Hers, the move telegraphs ambition: mainstream awareness, category leadership, and the normalization of conversations about personal health. It also signals confidence in the company’s ability to translate brand buzz into subscriber growth across multiple categories.
The concern is less about one commercial and more about what it implies. Brand advertising of that scale raises blended customer acquisition costs in the near term. If the company is simultaneously entering categories with structurally lower gross margins or higher churn risk, the payback window on new cohorts can extend, pressuring near-term profitability and cash flow.
The unit economics puzzle
Hims & Hers’ model hinges on a few inputs:
– Customer acquisition cost (CAC): How much it spends to add each new subscriber.
– Retention and cohort behavior: How long customers stay and how consistently they reorder.
– Cross-sell and ARPU expansion: How effectively the company moves customers into additional treatments.
– Gross margin by product: Prescription categories vary widely, and GLP-1s in particular can compress margins due to high cost of goods.
– Operating leverage: Whether marketing, fulfillment, and clinical costs scale more slowly than revenue.
Investors like the company’s historically strong growth and brand recognition. But expansion into weight loss, while potentially transformative, changes the math. The drugs are expensive, competition is intense, supply can be inconsistent, and regulators are watching compounded alternatives closely. If marketing ramps faster than the company can prove durable retention and attractive margins in these newer lines, short-term profitability could slip.
Regulatory and competitive overhangs
Telehealth remains under regulatory scrutiny. Any shifts to compounding guidance, teleprescribing rules, or pharmacy practices could affect availability and economics, particularly in weight management. Meanwhile, competition is heating up across every front: other digital clinics, traditional providers leaning into virtual care, retail pharmacies expanding clinical services, and consumer brands pushing OTC solutions. That rivalry can push up marketing costs and limit pricing power.
The bull case
Supporters argue that Hims & Hers is playing a long game it’s well suited to win:
– Brand power and mainstream reach can depress future CAC, especially if top-of-funnel investment is followed by targeted performance marketing.
– A larger platform enables better procurement, logistics, and clinical workflows, expanding contribution margins over time.
– Cross-sell across a broad catalog increases lifetime value, reducing reliance on any single category’s margins.
– Normalizing stigmatized topics creates organic word-of-mouth and retention benefits that don’t fully show up in early cohort economics.
The bear case
Skeptics counter that:
– Big-ticket brand spending risks overpaying for attention unless conversion paths are airtight.
– Weight-loss economics are vulnerable to drug pricing, supply constraints, and policy changes, all of which can whipsaw margins.
– As the company matures, the “easy growth” from early adopters gives way to a tougher, more expensive customer pool.
– Complexity grows with category sprawl, raising the odds of operational missteps or inconsistent patient experiences.
What to watch in upcoming quarters
For investors trying to separate sizzle from substance, a handful of metrics and disclosures matter more than the ad’s creative:
– CAC and payback period by cohort, especially those acquired around the Super Bowl flight.
– Gross margin by category and blended gross margin trajectory as the mix shifts.
– Ad spend as a percentage of revenue and marketing efficiency (e.g., contribution margin after marketing).
– Churn, reorder rates, and cross-sell penetration within newer categories like weight management.
– Cash generation, including operating cash flow and capital needs for inventory and pharmacy operations.
– Regulatory updates affecting compounding and teleprescribing, and any shifts in supply relationships for high-demand drugs.
What success looks like
In the near term, success would mean the Super Bowl halo drives a sustained increase in qualified traffic and conversions without an outsized rise in CAC; that those customers exhibit retention in line with, or better than, historical cohorts; and that category mix shifts do not erode blended gross margins. Over the medium term, investors will want to see operating leverage — marketing and clinical costs rising more slowly than revenue — and clearer guardrails around profitability targets even as the company explores new care areas.
The bottom line
Hims & Hers is choosing a classic growth-company tradeoff: spend now to cement brand leadership and expand into large, adjacent markets, with an eye toward monetizing that scale later. The Super Bowl ad underscores that ambition, but it also heightens scrutiny of unit economics precisely when the company is pushing into categories that can strain margins. If execution keeps CAC in check, retention stays strong, and newer offerings prove both sticky and profitable, the investment will look prescient. If not, the biggest stage in advertising could become a symbol of overly aggressive expansion at the expense of near-term profits.
